Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 1999

View Archived Issues

Alexion advances MI product, UniGraft

ImClone Systems files IND in U.S. for antiangiogenic agent

Progress in proceedings concerning Celltech Chiroscience and Medeva merger

Pivotal trials of Optison ultrasound imaging agent begin in Japan

Pharmos seeks approval for Loterox in the U.K.

Genentech's rhuMAb-VEGF will move to phase III study

WHO takes over to ensure continued availability of antitrypanosomal agent

Searle patents new series of p38 MAP kinase inhibitors for inflammation

Another megamerger proposed: Pharmacia & Upjohn and Monsanto

Nonpeptide agents which mimic peptide T binding to CD4 cell receptors as new treatments for HIV

Synthetic immunogens useful for preparation of HPV preventive vaccine

Preclinical studies validate Nabi's novel approach to treating and preventing nicotine addiction

Novel dopaminergic agents synthesized and tested at AHP

Inhibitors of CPT-I from Sigma-Tau useful for hyperglycemic states, cardiovascular disorders

Roberts launches emergency contraceptive in Canada

Glaxo Wellcome files for approval of first triple combination anti-HIV therapy

PPG superior to nonselective mGluR agonists in audiogenic seizure model

Phase I clinical trial initiated with OSI's second anticancer agent

Remacemide for resistant epilepsy: preliminary data from meta-analysis

German launch announced for flu drug

New class I mGluR antagonist prevents seizure-induced hippocampal damage

Swiss regulatory authorities grant Visudyne Therapy its first approval

Add-on stiripentol produces high response rate in intractable epilepsy syndrome

Tetrapeptide with potent antiinflammatory, antiarthritic effects emerges from India

Warner-Lambert files IND for oral calcitonin product for osteoporosis

New antiplatelet pyridazinones presented by Chinese university investigators

Benzimidazole antidiabetic agent advances through the pipeline in Japan and overseas

NicOx commences phase IIa trial with treatment for Paget's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...